Science Snapshot: Understanding Cholesterol Numbers Under New Guidelines

Cardiovascular medicine underwent a landmark shift with the release of the March 13, 2026 ACC/AHA Dyslipidemia Guideline Update. Issued jointly by the American College of Cardiology and the American Heart Association, these updated guidelines replaced legacy recommendations with individualized risk assessment targets. Central to this framework is the AHA PREVENT Risk Calculator, which official guidelines now use instead of the older 2013 Pooled Cohort Equations. This tool estimates 10-year and 30-year cardiovascular risk for adults aged 30 to 79 by incorporating metabolic markers, kidney function metrics, and social determinants of health into your personalized score.

Under these guidelines, low-density lipoprotein (LDL-C) target goals depend on your calculated baseline risk level. For low-risk individuals, maintaining an LDL-C below 100 mg/dL remains the primary target. For intermediate-risk patients, doctors aim for an LDL-C target below 70 mg/dL. For high-risk and very high-risk patients—such as those with prior cardiovascular events, peripheral artery disease, or diabetes with microvascular complications—the target LDL-C drops to below 55 mg/dL.

The updated guidelines also emphasize critical secondary lipid targets, specifically non-HDL-C and Apolipoprotein B (ApoB). For high-risk individuals, the non-HDL-C target goal is below 100 mg/dL, while the target drops to below 85 mg/dL for very high risk. Similarly, ApoB targets are now set at below 70 mg/dL for high risk and below 55 mg/dL for very high risk. These measurements reflect the actual quantity of plaque-causing particles in your blood.

Age plays a distinct role in primary prevention guidelines. Recommendations from the U.S. Preventive Services Task Force advise initiating statin therapy for primary prevention in adults aged 40 to 75 who exhibit cardiovascular risk factors alongside a 10-year risk of 10 percent or higher (Grade B) or 7.5 to 10 percent (Grade C). However, for adults aged 76 and older without prior events, the task force concludes that evidence remains insufficient to evaluate initiating statin therapy (Grade I), reinforcing the need for personalized discussions with your physician.